Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.
The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.
The user is experimenting with topical melatonin for hair loss by dissolving melatonin tablets in a solution, but is having trouble with dissolution and is curious about others' methods of application and any effects on energy levels. They mention considering mixing with minoxidil but have not done so, and suggest that melatonin is best used at night.
DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.
The conversation is about using GHK-CU peptide for hair regrowth. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments for hair loss.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.
A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.
A user shared 4-month progress pictures using a daily Hims fin/min/ketoconazole/biotin hybrid spray for hair loss, reporting positive results. Suggestions included adding microneedling to the routine.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.
Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.
Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.
People are humorously discussing unconventional and satirical uses of minoxidil, such as drinking it or injecting it, and the potential absurd consequences. The conversation also touches on the ineffectiveness and risks of these methods compared to proper topical application with microneedling.
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
A user received a custom topical treatment for hair loss from Rootsbyga, which includes minoxidil and possibly other ingredients to enhance its effectiveness. The initial test cost $120, and the monthly topical costs around $70, with concerns about long-term use of steroids like hydrocortisone.
The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The conversation discusses using gartanin from mangosteen mixed with castor oil to degrade the androgen receptor for hair loss treatment. Alternatives like setipiprant, minoxidil, and dermastamping are also mentioned, with concerns about cost and potential side effects.